+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030- Product Image
Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030- Product Image
Sale

Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6017361
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The generic oncology drugs market is transforming as regulatory shifts, digital innovation, and supply chain agility reshape access to cost-effective cancer care. Decision-makers are now navigating complex strategies to ensure quality, affordability, and resilience in a dynamic therapeutic sector.

Market Snapshot: Global Generic Oncology Drugs Market Growth

The Generic Oncology Drugs Market grew from USD 38.74 billion in 2024 to USD 41.51 billion in 2025. Projected to continue at a CAGR of 6.95%, the market is expected to reach USD 58.01 billion by 2030. This trajectory reflects greater adoption across healthcare systems, increasing demand for patent-expired therapies, and strategic regulatory support for generic alternatives.

Scope & Segmentation

This report comprehensively analyzes the expanding role of generic oncology therapeutics across global markets. Senior leaders gain actionable segmentation spanning product types, technology adoption, and critical distribution models. Coverage includes:

  • Drug Types: Biologics, Small Molecule
  • Indications: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Prostate Cancer
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • Routes of Administration: Intravenous, Oral, Subcutaneous
  • Therapy Lines: First-Line, Second-Line, Third-Line Plus
  • Mechanisms of Action: Chemotherapy, CAR-T Therapy, Checkpoint Inhibitors, Monoclonal Antibodies, Tyrosine Kinase Inhibitors
  • Formulations: Liquid, Lyophilized Powder, Tablet
  • Regions: Americas (US, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including UK, Germany, France, Russia, and more), Asia-Pacific (China, India, Japan, Australia, South Korea, Southeast Asia)
  • Leading Companies: Teva, Sandoz, Pfizer, Fresenius Kabi, Hikma, Viatris, Dr. Reddy’s, Aurobindo, Sun Pharma, Cipla

Technological advances driving this market include modular bioreactors, continuous flow synthesis, and digital innovation in logistics and analytics, alongside increased use of supply chain security systems.

Key Takeaways for Senior Stakeholders

  • Patent expiries and biosimilar introductions are fueling competitive intensity, supporting broader access to advanced oncologic care.
  • Streamlined regulatory pathways and harmonized international guidelines accelerate time-to-market, prompting greater investment in robust manufacturing quality systems.
  • Healthcare systems are leveraging value-based purchasing, driving adoption of generics with demonstrated clinical equivalence and economic benefit.
  • Digital integration in quality control, batch tracing, and supply chain management strengthens risk mitigation and compliance, supporting sustained product delivery.
  • Manufacturers increasingly adopt modular and flexible production approaches, mitigating disruptions from raw material shortages or geopolitical shifts.
  • Regional strategic variations—such as local sourcing initiatives and public-private partnerships—shape market access and influence uptake across the Americas, EMEA, and Asia-Pacific.

Potential Tariff Impact on Supply Chain and Market

Forthcoming United States tariff adjustments could influence supply chain stability, especially for APIs sourced internationally. Organizations may need to adapt with localized manufacturing, inventory strategies, or renegotiated supplier contracts, affecting operational costs and responsiveness in the generic oncology segment.

Methodology & Data Sources

Research combines primary interviews with industry experts, detailed analysis of regulatory filings, trade publications, and proprietary databases. Quantitative modeling supports segmentation and scenario forecasting. Rigorous cross-validation and peer review ensure reliable insights on market dynamics and underlying trends.

Why This Report Matters

  • Informs strategic planning with deep dives into therapeutic segments, regulatory evolutions, and supply risk factors tailored to the generic oncology market.
  • Enables actionable decision-making for investment in manufacturing technologies, supplier diversification, and regulatory engagement.
  • Supports budgeting and policy alignment by mapping regional nuances and policy-driven challenges that impact drug access and competitive positioning.

Conclusion

This analysis equips senior leaders to navigate evolving opportunities and challenges in the generic oncology drugs market. Future growth hinges on adaptive supply chain strategies, regulatory alignment, and continuous manufacturing innovation for improved patient access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of biosimilar immuno-oncology agents to improve access in emerging markets
5.2. Rising price erosion and competitive generic entry after high-profile oncology drug patent expirations
5.3. Integration of advanced continuous manufacturing to reduce costs of generic oncology compound production
5.4. Regulatory acceleration pathways for biosimilars shaping market entry timelines for oncology treatments
5.5. Strategic partnerships between CDMOs and generic drugmakers to address oncology supply chain challenges
5.6. Increasing demand for oral generic tyrosine kinase inhibitors with improved patient adherence support programs
5.7. Growing focus on personalized dosing solutions in generic oncology to enhance therapeutic outcomes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Generic Oncology Drugs Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecule
9. Generic Oncology Drugs Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Leukemia
9.5. Lung Cancer
9.6. Lymphoma
9.7. Prostate Cancer
10. Generic Oncology Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Generic Oncology Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Generic Oncology Drugs Market, by Therapy Line
12.1. Introduction
12.2. First-Line
12.3. Second-Line
12.4. Third-Line Plus
13. Generic Oncology Drugs Market, by Mechanism Of Action
13.1. Introduction
13.2. Chemotherapy
13.3. Immunotherapy
13.3.1. CAR-T Therapy
13.3.2. Checkpoint Inhibitors
13.4. Targeted Therapy
13.4.1. Monoclonal Antibodies
13.4.2. Tyrosine Kinase Inhibitors
14. Generic Oncology Drugs Market, by Formulation
14.1. Introduction
14.2. Liquid
14.3. Lyophilized Powder
14.4. Tablet
15. Americas Generic Oncology Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Generic Oncology Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Generic Oncology Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Teva Pharmaceutical Industries Ltd
18.3.2. Sandoz International GmbH
18.3.3. Pfizer Inc
18.3.4. Fresenius Kabi AG
18.3.5. Hikma Pharmaceuticals PLC
18.3.6. Viatris Inc
18.3.7. Dr. Reddy’s Laboratories Ltd
18.3.8. Aurobindo Pharma Limited
18.3.9. Sun Pharmaceutical Industries Limited
18.3.10. Cipla Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. GENERIC ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. GENERIC ONCOLOGY DRUGS MARKET: RESEARCHAI
FIGURE 30. GENERIC ONCOLOGY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. GENERIC ONCOLOGY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. GENERIC ONCOLOGY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GENERIC ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 130. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 131. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 132. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 133. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 134. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 135. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 232. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 233. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 246. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 247. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 250. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 251. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 258. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 259. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 264. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 265. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 286. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 287. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 294. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 295. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 300. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 301. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 302. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 303. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 304. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 305. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 312. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 313. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 314. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 315. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 318. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 319. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 320. SPAIN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES G

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Generic Oncology Drugs market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Pfizer Inc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Viatris Inc
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 41.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 58.01 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Small Molecule API - Global Strategic Business Report - Product Image

Small Molecule API - Global Strategic Business Report

  • Report
  • 379 Pages
  • Global
From
Small Molecule API Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Small Molecule API Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 132 Pages
  • Global
From
Small Molecule API Market Report 2025 - Product Image

Small Molecule API Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hedgehog Pathway Inhibitors Market by Indication (Acute Myeloid Leukemia, Basal Cell Carcinoma, Medulloblastoma), Product Type (Antibody, RNAi, Small Molecule), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Hedgehog Pathway Inhibitors Market by Indication (Acute Myeloid Leukemia, Basal Cell Carcinoma, Medulloblastoma), Product Type (Antibody, RNAi, Small Molecule), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
FASN Inhibitor Market by Indication (Breast Cancer, Hepatocellular Carcinoma, Ovarian Cancer), Product Type (Antibody Inhibitor, Peptide Inhibitor, Small Molecule), Formulation, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

FASN Inhibitor Market by Indication (Breast Cancer, Hepatocellular Carcinoma, Ovarian Cancer), Product Type (Antibody Inhibitor, Peptide Inhibitor, Small Molecule), Formulation, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From

About the Generic Oncology Drug Market

The Generic Oncology Drug market is a subset of the larger Generic Drug market. Generic Drugs are copies of brand-name drugs that have the same active ingredients, dosage form, strength, route of administration, safety, efficacy, and intended use as the original drug. Generic Oncology Drugs are used to treat cancer and are typically much less expensive than their brand-name counterparts. Generic Oncology Drugs are typically available in oral, injectable, and topical forms. Generic Oncology Drugs are subject to the same regulatory standards as brand-name drugs, and must meet the same safety and efficacy requirements. Generic Oncology Drugs are typically available in the same dosage forms and strengths as their brand-name counterparts. Some companies in the Generic Oncology Drug market include Mylan, Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.